None listed
Conditions
Interventions
Drug : Experimental group: Mosapride 5mg and placebo of rifaximin tid for 2 weeks
Two active comparator groups (Rifaximin group and mosapride, rifaximin combination group)
Rifaximin group: rifaximin 4
Sponsors
The Catholic University of Korea, St. Vincent's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) patients of age 20 to 80 2) patients diagnosed with small intestinal bacterial overgrowth in the glucose breath test
Exclusion criteria
Exclusion criteria: 1) Patients who were treated with antibiotics within 3 months 2) Patients diagnosed with gastrointestinal stricture or obstruction at the endoscopy or upper gastrointestinal series 3) Patients with previous gastrointestinal surgery, except for appendectomy 4) Patients who have gastrointestinal bleeding, mechanical obstruction, or perforation 5) Patients who have severe organ dysfunction, such as renal dysfunction or hepatic dysfunction 6) Patients who were treated with medication, such as prokinetics, histamine receptor antagonists, proton pump inhibitors, anticholinergics, antidepressant within 2 weeks before the study 7) Allergic reaction for experimental medicine 8) Improper patient in the study, according to judgement of researcher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rate of small intestinal bacterial overgrowth | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of symptom;The results of glucose breath test | — |
Countries
Korea, Republic of
Contacts
Public ContactChang-Nyol Paik
The Catholic University of Korea, St. Vincent's Hospital
Outcome results
None listed